# A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

> **NCT02612662** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (actual)

## Conditions studied

- Non-alcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** AZD4076
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02612662
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-24
- **Primary completion:** 2017-11-04
- **Final completion:** 2025-10-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02612662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02612662, "A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02612662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*